Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort

• Published in: Alimentary pharmacology & therapeutics Vol. 49; no. 10; pp. 1323 - 1333
• Main Authors: Scheiner, Bernhard, Kirstein, Martha M., Hucke, Florian, Finkelmeier, Fabian, Schulze, Kornelius, von Felden, Johann, Koch, Sandra, Schwabl, Philipp, Hinrichs, Jan B., Waneck, Fredrik, Waidmann, Oliver, Reiberger, Thomas, Müller, Christian, Sieghart, Wolfgang, Trauner, Michael, Weinmann, Arndt, Wege, Henning, Trojan, Jörg, Peck‐Radosavljevic, Markus, Vogel, Arndt, Pinter, Matthias
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2019; John Wiley and Sons Inc
• Subjects: Aged; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - therapeutic use; Apoptosis; Austria; Carcinoma, Hepatocellular - drug therapy; Cell death; Diarrhea; Disease control; Female; Germany; Hepatitis; Hepatocellular carcinoma; Humans; Immunotherapy; Liver cancer; Liver Neoplasms - drug therapy; Male; Middle Aged; Monoclonal antibodies; Nivolumab - therapeutic use; Original; Pembrolizumab; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death Protein‐1 Targeted Immunotherapy for Hepatocellular Carcinoma; Proteins; Pruritus; Retrospective Studies; Safety; Targeted cancer therapy; Austria; Germany

Summary Background Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real‐world cohort of patients with advanced hepa...